TY - JOUR
T1 - European bio-naïve spondyloarthritis patients initiating TNF inhibitor
T2 - time trends in baseline characteristics, treatment retention and response
AU - Christiansen, Sara Nysom
AU - Ørnbjerg, Lykke Midtbøll
AU - Rasmussen, Simon Horskjær
AU - Loft, Anne Gitte
AU - Askling, Johan
AU - Iannone, Florenzo
AU - Zavada, Jakub
AU - Michelsen, Brigitte
AU - Nissen, Michael
AU - Onen, Fatos
AU - Santos, Maria Jose
AU - Pombo-Suarez, Manuel
AU - Relas, Heikki
AU - Macfarlane, Gary J.
AU - Tomsic, Matija
AU - Codreanu, Catalin
AU - Gudbjornsson, Bjorn
AU - Van der Horst-Bruinsma, Irene
AU - Di Giuseppe, Daniela
AU - Glintborg, Bente
AU - Gremese, Elisa
AU - Pavelka, Karel
AU - Kristianslund, Eirik Klami
AU - Ciurea, Adrian
AU - Akkoc, Nurullah
AU - Barcelos, Anabela
AU - Sánchez-Piedra, Carlos
AU - Peltomaa, Ritva
AU - Jones, Gareth T.
AU - Rotar, Ziga
AU - Ionescu, Ruxandra
AU - Grondal, Gerdur
AU - Van de Sande, Marleen G.H.
AU - Laas, Karin
AU - Østergaard, Mikkel
AU - Hetland, Merete L.
N1 - The authors acknowledge Novartis Pharma AG and IQVIA for supporting the EuroSpA collaboration.
Funding: This work was supported by Novartis. Novartis had no influence on the data collection, statistical analyses, manuscript preparation or decision to submit.
PY - 2022/9/1
Y1 - 2022/9/1
N2 - OBJECTIVES: To investigate time trends in baseline characteristics and retention, remission and response rates in bio-naïve axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA) patients initiating TNF inhibitor (TNFi) treatment. METHODS: Prospectively collected data on bio-naïve axSpA and PsA patients from routine care in 15 European countries were pooled. Three cohorts were defined according to year of TNFi initiation: A (1999-2008), B (2009-2014) and C (2015-2018). Retention, remission and response rates were assessed at 6, 12 and 24 months. RESULTS: In total, 27 149 axSpA and 17 446 PsA patients were included. Cohort A patients had longer disease duration compared with B and C. In axSpA, cohort A had the largest proportion of male and HLA-B27 positive patients. In PsA, baseline disease activity was highest in cohort A. Retention rates in axSpA/PsA were highest in cohort A and differed only slightly between B and C. For all cohorts, disease activity decreased markedly from 0 to 6 months. In axSpA, disease activity at 24 months was highest in cohort A, where also remission and response rates were lowest. In PsA, remission rates at 6 and 12 months tended to be lowest in cohort A. Response rates were at all time points comparable across cohorts, and less between-cohort disease activity differences were seen at 24 months. CONCLUSION: Our findings indicate that over the past decades, clinicians have implemented more aggressive treatment strategies in spondyloarthritis. This was illustrated by shorter disease duration at treatment initiation, decreased retention rates and higher remission rates during recent years.
AB - OBJECTIVES: To investigate time trends in baseline characteristics and retention, remission and response rates in bio-naïve axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA) patients initiating TNF inhibitor (TNFi) treatment. METHODS: Prospectively collected data on bio-naïve axSpA and PsA patients from routine care in 15 European countries were pooled. Three cohorts were defined according to year of TNFi initiation: A (1999-2008), B (2009-2014) and C (2015-2018). Retention, remission and response rates were assessed at 6, 12 and 24 months. RESULTS: In total, 27 149 axSpA and 17 446 PsA patients were included. Cohort A patients had longer disease duration compared with B and C. In axSpA, cohort A had the largest proportion of male and HLA-B27 positive patients. In PsA, baseline disease activity was highest in cohort A. Retention rates in axSpA/PsA were highest in cohort A and differed only slightly between B and C. For all cohorts, disease activity decreased markedly from 0 to 6 months. In axSpA, disease activity at 24 months was highest in cohort A, where also remission and response rates were lowest. In PsA, remission rates at 6 and 12 months tended to be lowest in cohort A. Response rates were at all time points comparable across cohorts, and less between-cohort disease activity differences were seen at 24 months. CONCLUSION: Our findings indicate that over the past decades, clinicians have implemented more aggressive treatment strategies in spondyloarthritis. This was illustrated by shorter disease duration at treatment initiation, decreased retention rates and higher remission rates during recent years.
KW - axial spondyloarthritis
KW - psoriatic arthritis
KW - remission
KW - response
KW - time trends
KW - TNFi retention
UR - http://www.scopus.com/inward/record.url?scp=85135873577&partnerID=8YFLogxK
U2 - 10.1093/rheumatology/keab945
DO - 10.1093/rheumatology/keab945
M3 - Article
C2 - 34940840
AN - SCOPUS:85135873577
SN - 1462-0324
VL - 61
SP - 3799
EP - 3807
JO - Rheumatology (Oxford, England)
JF - Rheumatology (Oxford, England)
IS - 9
ER -